Celltrion Group's 3 Companies Decide on Cash and Stock Dividends Simultaneously and Stock Dividends... "Enhancing Shareholder Value"

Incheon Songdo Celltrion Plant 2 exterior./Photo by Hyunmin Kim kimhyun81@

[Asia Economy Reporter Lee Gwan-joo] Celltrion Group's listed companies Celltrion, Celltrion Healthcare, and Celltrion Pharm each decided on simultaneous stock and cash dividends or stock dividends through board resolutions on the 16th. The dividend record date is set for the 31st of this month.

Celltrion decided on a cash dividend of 375 KRW per common share and a stock dividend of 0.04 shares per common share. The total cash dividend amounts to approximately 51.7 billion KRW, and the total number of dividend shares is 5,511,708 shares.

Celltrion Healthcare decided on a cash dividend of 130 KRW per common share and a stock dividend of 0.04 shares per common share. The total cash dividend and total dividend shares are 20.2 billion KRW and 6,204,399 shares, respectively.

Both Celltrion and Celltrion Healthcare plan to share the company's value through simultaneous cash and stock dividends again this year, following last year, while returning part of the profits to shareholders. However, considering the economic situation and cash flow capacity, this year’s dividend policy focuses on sharing future value, doubling the stock dividend from 0.02 shares per share last year to 0.04 shares.

When converting this year’s dividend amounts and treasury stock purchases of the two companies into shareholder return ratios based on last year’s net income, they are 57.3% and 72.9%, respectively, surpassing the average shareholder return ratio of 15% for the top 10 companies by market capitalization last year. Celltrion and Celltrion Healthcare acquired approximately 280 billion KRW and 91 billion KRW worth of treasury shares, respectively, this year to enhance shareholder value.

Celltrion Pharm, instead of cash dividends, applies the highest stock dividend rate among the three companies again this year. A stock dividend of 0.05 shares per common share is planned, with a total of 1,879,002 dividend shares. This decision reflects the rapidly growing momentum and cash flow of Celltrion Pharm.

All dividends and dividend shares will be finally approved at the regular shareholders' meeting scheduled for March next year and then paid to shareholders.

A Celltrion Group official said, "This year’s dividends are a decision made with gratitude to shareholders who supported the company’s growth despite the difficult market conditions such as the worsening global economic situation, considering the circumstances of each company comprehensively. Celltrion Group will do its best to become a representative co-growth company that can grow together with shareholders and share the profits generated during growth."

This content was produced with the assistance of AI translation services.